Patents Assigned to Japan Immunoresearch Laboratories Co., Ltd.
-
Patent number: 7241861Abstract: A high-density lipoprotein-reactive peptide or a foam cell-reactive peptide as set forth in the following (a) or (b): (a) a peptide comprising the amino acid sequence represented by SEQ ID NO: 1; and (b) a peptide comprising an amino acid sequence derived from the amino acid sequence as specified in the above (a) by substitution, deletion, addition, or insertion of one or more amino acid residues and being capable of specifically binding to high-density lipoprotein cholesterol or withdrawing cholesterol from foam cells. Thus, peptides having novel amino acid sequences and being capable of specifically binding to HDL cholesterol or withdrawing cholesterol from foam cells are provided. These peptides are useful as drugs for various diseases caused by arteriosclerosis, lipid metabolic errors, and peripheral cholesterosis.Type: GrantFiled: May 15, 2002Date of Patent: July 10, 2007Assignee: Japan Immunoresearch Laboratories Co., Ltd.Inventors: Manabu Niimi, Kazushi Kanatani, Masakazu Adachi
-
Publication number: 20040166103Abstract: The invention provides a technology which utilizes donor lymphocyte infusion and by which malignant tumor can be treated without causing such an adverse effect as graft versus host disease. Thus, a method for the treatment of malignant tumor is provided which comprises performing, in a patient requiring such treatment, donor lymphocyte infusion for the graft versus tumor reaction-based treatment of tumor and then performing radiation treatment, infusion of lymphocytes derived from the host or a third party identical in HLA type to the host, and intra bone marrow-bone marrow transplantation using bone marrow cells derived from the host or a third party identical in HLA type to the host, for the prevention and treatment of the graft versus host disease induced by the donor lymphocyte infusion.Type: ApplicationFiled: February 26, 2004Publication date: August 26, 2004Applicants: KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD., JAPAN IMMUNORESEARCH LABORATORIES CO., LTD.Inventors: Susumu Ikehara, Yasushi Adachi, Yasuhiro Suzuki
-
Patent number: 6713252Abstract: Described is a method of removing and reducing HCV from the blood of an HCV-infected patient, which comprises carrying out, once a day for at least 5 straight days, a treatment of bringing the blood into contact with an adsorptive carrier having a higher affinity for infected, activated and/or defective leukocytes than for uninfected leukocytes. The treatment according to the present invention makes it possible to markedly reduce the blood HCV level of a patient suffering from Hepatitis C, thereby enabling antiviral therapy, for example, treatment with interferon. This brings a drastic improvement in the cure rate for Hepatitis C.Type: GrantFiled: June 27, 2002Date of Patent: March 30, 2004Assignee: Japan Immunoresearch Laboratories Co., Ltd.Inventors: Kouji Sawada, Takashi Shimoyama
-
Publication number: 20030152569Abstract: Described is a method of removing and reducing HCV from the blood of an HCV-infected patient, which comprises carrying out, once a day for at least 5 straight days, a treatment of bringing the blood into contact with an adsorptive carrier having a higher affinity for infected, activated and/or defective leukocytes than for uninfected leukocytes. The treatment according to the present invention makes it possible to markedly reduce the blood HCV level of a patient suffering from Hepatitis C, thereby enabling antiviral therapy, for example, treatment with interferon. This brings a drastic improvement in the cure rate for Hepatitis C.Type: ApplicationFiled: June 27, 2002Publication date: August 14, 2003Applicant: JAPAN IMMUNORESEARCH LABORATORIES CO., LTD.Inventors: Kouji Sawada, Takashi Shimoyama
-
Patent number: 6498007Abstract: The invention relates to a method for the removal of leucocytes from blood which comprises bringing blood that comprises infected leucocytes into contact with an adsorbent carrier that has a greater affinity for infected, activated and/or defective leucocytes than for uninfected leucocytes especially cellulose acetate. The method can be used in the apheresis treatment of diseases caused by pathogenic organisms, for example, HIV, HCV or malaria. It is especially useful for treatment of HIV.Type: GrantFiled: November 17, 2000Date of Patent: December 24, 2002Assignee: Japan Immunoresearch Laboratories Co., Ltd.Inventors: Masakazu Adachi, Toshifumi Hibi
-
Patent number: 6383481Abstract: This invention relates to a method of transplanting hemopoietic stem cells which Comprises subjecting a recipient to a radiation treatment using an effective exposure dose for hemopoietic stem cell transplantation in advance and administering hemopoietic stem cells from a donor from the portal vein. By this method the graft failure/rejection of donor cells can be avoided to thereby maintain the transplant in satisfactory condition.Type: GrantFiled: March 10, 1999Date of Patent: May 7, 2002Assignee: Japan Immunoresearch Laboratories Co., Ltd.Inventors: Susumu Ikehara, Muneo Inaba, Kenji Takeuchi, Taketoshi Kushida
-
Patent number: 5582817Abstract: Zinc salts, zinc complexes or salts thereof of a compound selected from the group consisting of nicotinamides, picolinamides, 3,4-dihydroxybenzoic acids, amino acids, peptides, hinokitiols and pyridine carboxylic acids represented by formula (1): ##STR1## possess a metallothionein inducing effect, effect of suppressing the production of sunburn cells, and therefore, useful as cosmetics and as drugs which are for ameliorating sunburn, preventing sunburn, ameliorating skin diseases, relieving irradiation disorders, and the like.Type: GrantFiled: October 1, 1993Date of Patent: December 10, 1996Assignees: Otsuka Pharmaceutical Co., Ltd., Japan Immunoresearch Laboratories Co., Ltd.Inventors: Yoshiro Otsu, Yaeno Arima, Katsuyuki Nakajima, Masakazu Adachi, Tsutomu Muramatsu, Katsumi Hanada
-
Patent number: 5567443Abstract: A method of treating inflammatory diseases, in which peripheral blood of a patient suffering from an inflammatory disease is made into contact with a carrier whose affinity for inflammation-associated cells is higher than that for lymphocytes, and the thus-obtained treated blood is returned to the patient.According to the present invention, inflammatory diseases can be promptly treated without causing adverse side effects to patients, because drug therapy is not needed.Type: GrantFiled: June 20, 1994Date of Patent: October 22, 1996Assignees: Japan Immunoresearch Laboratories Co., Ltd., Sekisui Chemical Co., Ltd.Inventors: Nobuhito Kashiwagi, Syojiroh Asakura, Tatsuo Ide, Masato Sakurai, Masakazu Adachi, Katsumi Tomiyoshi, Tsuneo Hirano
-
Patent number: 4552633Abstract: A fine particulate carrier for use in clinical testing which has a size of 0.5 to 20 microns and a process for producing thereof are herein disclosed.Type: GrantFiled: September 22, 1983Date of Patent: November 12, 1985Assignees: Japan Atomic Energy Research Institute, Japan Immunoresearch Laboratories Co., Ltd.Inventors: Minoru Kumakura, Isao Kaetsu, Mieko Suzuki, Masakazu Adachi